Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease

International Journal of Clinical Practice

Volumn 57, Issue 9, 2003, Pages 801-822

  Cantarovich, Felix ^a   Rangoonwala, B ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM ANTAGONIST; CANDESARTAN HEXETIL; CAPTOPRIL; CILAZAPRIL; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; TACROLIMUS; TELMISARTAN; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL RESEARCH; DEATH; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY TRANSPLANTATION; MICROALBUMINURIA; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; REVIEW;

ALBUMINURIA; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; PREDICTIVE VALUE OF TESTS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 0347589286     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (267)

1. Jacobson HR, Klahr S. Chronic renal failure: pathophysiology and management. Lancet 1991; 338: 419-423.
2. Locatelli F, Del Vechio L, Pozzoni P. The importance of early detection of chronic kidney disease. Nephrol Dial Transpl 2002; 17: 2-7.
3. Hornych A, Asmar R. Microalbuminuria and arterial hypertension. Presse Med. 1999; 28: 597-604.
4. Redon J. Renal protection by antihypertensive drugs: insights from microalbuminuria studies. J Hypertens 1998; 16: 2091-2100.
5. Remuzzi G. Cigarette smoking and renal function impairment. Am J Kidney Dis 1999; 33: 807-813.
6. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87.
7. Kussman MJ, Goldstein HH, Gleason RE. The clinical course of diabetic nephropathy. JAMA 1976; 236: 1861-1863.
8. Salahudeen AK. Halting progression of renal failure: consideration beyond angiotensin II inhibition. Nephrol Dial Transpl 2002; 17: 1871-1875.
9. The EUCLID Study Group. Randomized placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 36: 1787-1792.
10. Ravid M, Brosh D, Levi Z et al. Use of enalapril to attenuate decline in renal function in normotensive normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med 1998; 128: 982-988.
11. Anderson S, Rennke HG, Garcia DL et al. Short and long term effects of the antihypertensive therapy in the diabetic rat. Kidney Int 1989; 36: 525-536.
12. Perico N, Remuzzi G. Angiotensin II receptor antagonists and treatment of hypertension and renal disease. Curr Opin Nephrol Hypertens 1998; 7: 571-578.
13. Hollenberg NK, Williams GH. In: Hatano M, Ed. The renin angiotensin system, the kidney, and the pathogenesis of hypertension nephrology, vol 1. Tokyo: Springer-Verlag 1990; 272-279.
14. Griendling K, Lassegue B, Alexander R. Angiotensin receptors and their therapeutic implications. Ann Rev Pharmacol Toxicol 1996; 36: 281-306.
15. Tsusumi K, Stromberg C, Savedra J. Characterization of angiotensin II receptor subtypes in the rat spleen. Peptides 1992; 13: 291-296.
16. Kagami S, Border W, Miller DE et al. Angiotensin II stimulates extracellular matrix synthesis through induction of transforming growth factor beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437.
17. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACE inhibitors to angiotensin II antagonists. Kidney Int 2000; 57: 1803-1817.
18. Campistol JM, Inigo P, Jimenez W et al. Losartan decreases plasma levels of TGF-beta-1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999; 56: 714.
19. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456.
20. Chobanian MC, Julin CM. Angiotensin II stimulates ammoniagenesis in canine renal proximal tubule segments. Am J Physiol 1991; 260: 19-26.
21. Shimada K, Yazaki Y. Binding sites for angiotensin II in human mononuclear leucocytes. J Biochem 1978; 84: 1013-1015.
22. Nataraj CH, Oliverio MI, Mannon RB et al. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Investig 1999; 104: 1693-1701.
23. Weinstock J, Blum A. Granuloma macrophages in murine Schistosomiasis mansoni generate components of the angiotensin system. Cell Immunol 1984; 89: 39-45.
24. Lazarus D, Asc J, Fanburg B, Lanzillo J. Angiotensin converting enzyme (kininase II) mRNA production and enzymatic activity in human peripheral blood monocytes are induced by GM-CSF but not by other cytokines. Biochem Biophys Acta 1994; 1226: 12-18.
25. Diet F, Pratt RE, Berry GJ et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-2767.
26. Vance B, Kelly C. A nephritogenic T cell clone expresses components of the renin-angiotensin system in responsive to angiotensin II. J Am Soc Nephrol 1994; 5: 772.
27. Simon M, Engel D, Weinstock J, Roi L. The effect of angiotensin II on human mononuclear cell reactivity suppression of PHA-P-induced thymidine incorporation. Immunol Invest 1985; 14: 389-400.
28. Lijnen P, Fagard R, Petrov V. Cytosolic calcium changes induced by angiotensin II in human peripheral blood mononuclear cells are mediated via angiotensin II subtype I receptors. J Hypertens 1997; 15: 871-876.
29. Benediktsson H, Chea R, Davidoff A, Paul L. Antihypertensive drug treatment in chronic renal allograft rejection in the rat: effect on structure function. Transplantation 1996; 62: 1640-1642.
30. Mach F, Schonbeck U, Sukhova G et al. Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature 1998; 394: 200-203.
31. Foor F, Parent SA, Morin N et al. Calcineurin mediates inhibition by FK 506 and cyclosporine of recovery from a-factor arrest in yeast. Nature 1992; 360: 682-684.
32. Amuchastegui SC; Azzollini N, Mister M et al. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998; 9: 1948-1955.
33. Weber K. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol 1997; 17: 467-491.
34. Orosz CG. Endothelial activation and chronic allograft rejection. Clin Transpl 1994; 8: 299-303.
35. Hisada Y, Sagaya T, Tanaka S et al. An essential role of angiotensin II receptor type 1a in recipient kidney, not in transplanted peripheral blood leucocytes, in progressive immune-mediated injury. Lab Invest 2001; 81: 1243-1251.
36. Furukawa Y, Matsumori A, Hirozane T, Sasayama S. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. Circulation 1996; 93: 333-339.
37. Kobayashi J, Crawford S, Backer C et al. Captopril reduces graft coronary artery disease in a rat heterotopic transplant model. Circulation 1993; 88: 286-290.
38. Mackenzie H, Ziai F, Nagano H et al. Candesartan cilexetil reduces renal allograft injury in Fisher Lewis rats. J Hypertens 1997; 15: S21-S25.
39. Szabo A, Lutz J, Scleimer K et al. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int 2000; 57: 982-991.
40. Hancock WH, Whitley WL. Tullius SG et al. Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993; 56: 643-650.
41. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167-181.
42. Jain S, Furness PN, Nicholson ML. The role of transforming growth factor beta in chronic renal allograft nephropathy. Transplantation 2000; 69: 1759-1766.
43. Cuhaci B, Kumar MS, Bloom RD et al. Transforming growth factor-beta levels in human allograft chronic fibrosis correlate with rate of decline in renal function. Transplantation 1999; 68: 785-790.
44. Shin GT, Khanna A, Ding R et al. In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. Transplantation 1998; 65: 313.
45. Bicknell G, Williams S, Shaw J et al. Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants. Br J Surg 2000; 87: 1569.
46. Heeman UW, Azuma H, Tullius SG et al. The contribution of reduced functioning mass to chronic kidney allograft dysfunction in rats. Transplantation 1994; 58: 1317-1322.
47. Itoh H, Mukoyama M, Pratt RE et al. Multiple autocrine growth factors modulate vascular smooth muscle growth response to angiotensin II. J Clin Invest 1993; 91: 2268-2274.
48. Border WA, Okuda S, Languino, LR et al. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990; 346: 371-374.
49. Owens G. Control of hypertrophic versus hyperplastic growth of vascular smooth muscle cells. Am J Physiol 1989; 257: H1755-H1765.
50. Klahr S, Morrissey J. Angiotensin II and gene expression in kidney. Am J Kidney Dis 1998; 31: 171-176.
51. 1 plasma levels in a crossover trial in renal transplant patients. J Am Soc Nephrol 2001; 12: 822.
52. Gasenvoort RT, de Zeeuw, de Jong PE et al. Is the antiproteinuric effect ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-867.
53. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-1407.
54. Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35: 58-63.
55. Lin J, Valeri A M, Markowitz GS et al. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002; 73: 783-788.
56. De Mattos A, Bennett W. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333-346.
57. Lewis J, Helderman J. Is it time for ACE inhibitors in chronic allograft nephropathy. Am J Kidney Dis 2000; 35: 154-156.
58. Francis G. ACE inhibition in cardiovascular disease. N Engl J Med 2000; 342: 201-202.
59. Hisada Y, Sugaya T, Yamanouchi M et al. Angiotensin I plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest 1999; 103: 627-635.
60. Morrissey JJ. Angiotensin II: an immune costimulator? Am J Kidney Dis 2000; 36: 434-440.
61. Gekle M. Renal proximal tubular albumin reabsorption: daily prevention of albuminuria. News Physiol Sci 1998; 13: 5-11.
62. Schreiner GF. Renal toxicity of albumin and other lipoproteins. Curr Opin Nephrol Hypertens 1998; 54: 369-373.
63. Keen H, Chlouverakis C. An immunoassay method for urinary albumin at low concentrations. Lancet 1963; ii: 913-914.
64. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987; 31: 673-689.
65. Ibrahim HAA, Vora JP. Diabetic nephropathy. In: Baillère's clinical endocrinology and metabolism. London: Harcourt Publishers 1999; 239-264.
66. Diercks GF, van Boven AJ, Hillege JL et al. The importance of microalbuminuria as a cardiovascular risk indicator: a review. Can J Cardiol 2002; 18: 525-535.
67. Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? J Clin Hypertens 2001; 3: 99.
68. Stehouwer CDA, Naaauta JJP, Zeldenrust GC et al. Urinary albumin excretion, cardiovascular diseases and endothelial dysfunction in noninsulin dependent diabetes mellitus. Lancet 1992; 340: 319-323.
69. Damgaard EM, Froland A, Jorgensen OD, Mogensen CR. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300: 297-300.
70. Lydakis C, Lip GY. Microalbuminuria and cardiovascular risk. Q J Med 1998; 91: 381-391.
71. Torzeweski J, Torzeweski M, Browyer DE et al. C-reactive protein frequently localises with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 1386-1392.
72. Marshall SM. Screening for microalbuminuria which measurement? Diabet Med 1991; 8: 706-711.
73. Viberti OC, Mogensen CE, Passa P et al. St Vincent Declaration, 1994: guidelines for the prevention of diabetic renal failure. In: Mogensen CE, Ed. The kidney and hypertension in diabetes mellitus, 2nd edn. Boston: Kluwer, 1994; 515-527.
74. WHO Study Group on prevention of diabetes mellitus. Prevention of diabetes mellitus: report of a WHO study group. WHO Technical Reports, series 844. Geneva: WHO, 1994.
75. Consensus Development Conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1994; 17: 1357-1361.
76. Jerums O, Cooper M, Gilbert R et al. Microalbuminuria in diabetes. Med J Aust 1994; 161: 265-268.
77. Mogensen CE, Keane WF, Bennet PH et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-1084.
78. UK Microalbuminuria Collaborative Study Group. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. BMJ 1993; 306: 1235-1239.
79. Mathiesen FR, Runn B, Storm B et al. The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. Diabet Med 1995; 12: 482-487.
80. John L, Sunder Rao PSS, Kanagasabapathy AS. Rate of progression of albuminuria in type 2 diabetes. Diabetes Care 1994; 17: 888-890.
81. Gall M-A, Hougaard P, Borch-Johnson K, Parving HH. Risk factors for development of incipient and overt nephropathy in non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997; 314: 783-788.
82. Almadi T, Núvgaard K, Feldt-Rasmussen B, Deckert T. The predictive value of microalbuminuria in IDDM. Diabetes Care 1994; 17: 120-125.
83. Viberti GC, Jarrett RJ, Mahmud U et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; i: 1430-1434.
84. Mogensen CD, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 311: 89-93.
85. Mathiesen ER, Oxens B, Johansen K et al. Incipient nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia 1984; 26: 406-410.
86. Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin dependent) diabetes mellitus. Diabetologia 1985; 28: 590-596.
87. Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin dependent diabetes: a 10-year follow-up study of 503 patients. Diabet Med 1988; 5: 126-134.
88. MacLeod JM, Lutale J, Marshall SM. Albumin excretion and vascular deaths in NIDDM. Diabetologia 1995; 38: 610-616.
89. Wisseman M, Viberti GC, Mackintosh D et al. Glycaemia, arterial pressure and microalbuminuria in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1984; 14: 401-405.
90. Elliot T, Ekstrand A, Franssila-Kallunki A et al. Multiple lipoprotein abnormalities in type 1 diabetic patients with renal disease. Diabetes 1996; 45: 974-979.
91. Muhlhauser I. Cigarette smoking in diabetes: an update. Diabet Med 1994; 11: 336-343.
92. Stephenson JM, Kenny S, Stevens LK et al, and the WHO Multinational Study Group. Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 1995; 12: 149-155.
93. Crippa G. Microalbuminuria in essential hypertension. J Hum Hypertens 2002; 16(suppl 1): S74-S77.
94. Pedrinelli R, Dell'Omo G, Di Bello V et al. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 2002; 16: 79-89.
95. Morelli E, Loon N, Meyer T et al. Effects of converting enzyme inhibition on barrier function in diabetic nephropathy. Diabetes 1990; 39: 76-82.
96. Mathiesen ER, Hommel E, Hansen HP et al. Randomized controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 1999; 319: 24-25
97. Björck S, Mulec H, Johnsen SA et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-343.
98. Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and the MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
99. Lewis JB, Berl T, Bain RP et al, and the Collaborative Study Group. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 1999; 34: 809-817.
100. Maschio G, Alberti D, Janin G et al, and the Angiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945.
101. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non diabetic nepropathies with non-nephrotic proteinuria. Lancet 1999; 351: 359-364.
102. Ruggenenti P, Perna A, Gherardi G et al. Renal function and requirement for dialysis in chronic nephropathy patients on long term ramipril: REIN follow-up trial. Gruppo Italiano di Study Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropaty. Lancet 1998; 352: 2020-2022.
103. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transpl 1999; 14: 648-654.
104. Barbagallo CM, Pinto A, Gallo S et al. Carotid atherosclerosis in renal transplant recipients: relationship with cardiovascular risk factors and plasma lipoproteins. Transplantation 1999; 67: 366-371.
105. Parving HH. Renoprotection in diabetics: genetic and non-genetic risk factors treatment. Diabetologia 1998; 41: 745-759.
106. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlation. Am J Physiol 1993; 265: 477-486.
107. Remuzzi G, Puntuorieri S, Battaglia C. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990; 85: 541-549.
108. Lewis E, Hunsicker L, Bain R, Rhode R, for the Collaborative Study Group. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
109. Rangoonwala B, Rosenthal J. Management of hypertension and its sequelae with ACE inhibition: biochemical, pharmacological and clinical aspects. Int J Clin Pract 1998; 52: 492-500.
110. Linz W, Wiemer G, Gohlke P et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-29.
111. Gohlke P, Lamberty K, Kuwer I et al. The long-term low-dose angiotensin-converting enzyme inhibitor treatment increases vascular cyclic guanosine 3′,5′-monophosphate. Hypertension 1993; 22: 682-687.
112. Hansson L, Lindholm LH, Ekbom T et al, for the Stop Hypertension 2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish trial in old patients with hypertension 2 study. Lancet 1999; 354: 1751-1756.
113. Staessen JA, Fagard R, Lutgarde T et al, for the Systolic hypertension in Europe (Syst-Eur) trial investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.
114. Hansson L, Lindholm LH, Niskanen L et al, for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) ranomised trial. Lancet 1999; 353: 611-616.
115. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145-153.
116. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1429-1435.
117. Packer M, Poole-Wilson PA, Armstrong PW et al, on behalf of the ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-2318.
118. Pfeffer MA, Branwald E, Moya LA et al, on behalf of the SAVE investigators. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-677.
119. The Acute Infarction Ramipril Efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
120. Hall AS, Murray GD, Ball SG, on behalf of AIREX study investigators. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) study. Lancet 1997; 349: 1493-1497.
121. Kober L, Torp-Pederson C, Carlson JE et al, for the Trandolapril Cardiac Evaluation (TRACE) study group. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-1676.
122. GISSI-3 (Gruppo Italiano per lo Studio della sopravvivenza nell' Infarto Miocardico). Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6- week mortality and ventricular function after myocardial infarction. Lancet 1994; 343: 1115-1122.
123. Lebovitz HE, Weigmann TB, Cnaan A et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 1994; 45: S150-S155.
124. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622.
125. Nielsen FS, Rossing P, Gall MA et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive non-insulin dependent diabetic subjects with diabetic nephropathy. Diabetes 1997; 46: 1182-1188.
126. The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial on effect of ramipril on decline in GFR and risk of terminal renal failure in proteinuric non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
127. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non diabetic nepropathies with non-nephrotic proteinuria. Lancet 1999; 351: 359.
128. Wright JT, Bakris G, Greene T et al, for the African American study of kidney disease and hypertension study group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
129. Brunner HR, Delacretaz E, Nussberger J et al. Angiotensin II antagonist DuP 753 and TCV 116. J Hypertens 1994; 12(suppl 1): S29-S34.
130. Reid IA. Interaction between Ang II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992; 262: E763-E778.
131. Peters H, Noble NA, Border WA. Targeting TGF-β1 over-expression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54: 1575-1583.
132. De Cotret PR. Relationships among diabetes, microalbuminuria, and ACE inhibition. J Cardiovasc Pharmacol 1998; 32(suppl 2): S9-S17.
133. Corlin PR, Spence JD, Williams B et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418-426.
134. Gillis JC, Markham A. Irbesartan: a review of its pharmacodynamic and phamacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54: 885-902.
135. Sever P. Candersartan cilexetil: a new long-acting, effective angiotensin II type 1 receptor blocker. J Hum Hypertens 1997; 11(suppl 2): S91-S95.
136. Stumpe KO, Haworth D, Höglund C et al. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press 1998; 7: 31-37.
137. Corea L, Cardoni O, Fogari R et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharm Ther 1996; 60: 341-346.
138. Mackay JH, Arcuri KE, Goldberg AI et al. Losartan and low-dose hydroclorothiazide in patients with essential hypertension. A double-blind placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278-285.
139. Plouin PF. Combination therapy with candersartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide. J Hum Hypertens 1997; 11(suppl 2): S65-S66.
140. Dahlöf B, Devereux RB, Kjeldsen SE et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
141. Gottlieb S, Dickestein K, Fleck E et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88: 1602-1609.
142. Havranek EP, Thomas I, Smith WB et al, for the Irbesartan Heart Failure Group. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol 1999; 33: 1174-1181.
143. Pitt B, Segal R, Martinez FA et al, on behalf of ELITE study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
144. Pitt B, Poole-Wilson P, Segal R et al, on behalf of the ELITE-II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial (Losartan Heart Failure Survival Study) ELITE II. Lancet 2000; 355: 1582-1587.
145. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
146. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee for the OPTIMAAL study group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction. The OPTIMAAL randomised trial. Lancet 2002; 306: 752-760.
147. Brenner BM, Cooper ME, De Zeeuw et al, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
148. Lewis EJ, Hunsicker LG, Clarke WR et al, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
149. Parving HH, Lehnert H, Brôchner-Mortensen J et al, for the irbesartan in patients with type 2 and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
150. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986, 77: 1993-2000.
151. Anderson S, Meyer TW, Rennke HG et al. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612-619.
152. Parving HH, Osterby R, Anderson PW, Hsueh WA. Diabetic nephropathy. In: Brenner BM, Ed. The kidney, 5th edn. Philadelphia: WB Saunders, 1996; 1864-1892.
153. Jover B, Mimran A. Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function. J Hypertens 1994; 12(suppl 9): S3-S7.
154. 1 antagonists. J Cardiovasc Pharmacol 1995; 26: 66-72.
155. Parving HH, Hommel E, Nielsen MD, Griese J. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ 1989: 299: 533-536.
156. Cambien F, Poirier O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-644.
157. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl-carboxy peptidase 1). Nucl Acids Res 1992; 20: 1433.
158. Parving HH, Hommel E, Mathiesen ER et al. Prevalence of micro-albuminuria, arterial hypertension, retinopathy and neuropathy in insulin-dependent diabetic patient. BMJ 1988; 296: 156-160.
159. Ligtenberg G, Blankestijn PJ, Oey OL et al. Reduction of sympathetic activity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-1328.
160. Ueda S, Elliot HL, Morton JJ et al. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension 1995; 25: 1266-1269.
161. Ueda S, Meredith PA. ACE (I/D) genotype as a predictors of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 1998; 98: 2148-2153.
162. Mizuiri S, Hemmi H, Inoue A et al. Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism. Nephron 1997; 75: 310-314.
163. Yoshida H, Mitarai T, Kawamura T et al. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin lnvest 1995; 96: 2162-2169.
164. McLaughlin KJ, Harden PN, Ueda S et al. The role of genetic polymorphism of angiotensin converting enzyme in the progression of renal diseases. Hypertension 1996; 28: 912-915.
165. Rigat B, Hubert C, Alhenc-Gelas F et al. An insertion-deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
166. Tarnow L, Rossing P, Gall M-A et al. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994; 17: 1247-1251.
167. Tomonaga P, Ujihara N, Yokoyama H et al. Angiotensin converting enzyme (ACE) gene polymorphism predicts the effect of ACE inhibitor (ACEI) on the progression of nephropathy in Japanese NIDDM patients [abstract]. J Am Soc Nephrol 1997; 8: 120A.
168. Parving HH, Jacobsen P, Tarnow L et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study? BMJ 1996; 313: 591-594.
169. Sheth JJ. Diabetes, microalbuminuria and hypertension. Clin Exp Hypertens 1999; 21: 61-68.
170. Viberti GC, Mogensen CE, Groop LC, Pants JF. Effects of captopril on progression to clinical proteinuria in patients with insulin dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271: 275-279.
171. Marre M, Chatelier G, Leblanc H et al. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988; 297: 1092-1095.
172. O'Donnell MJ, Rowe BR, Lawson N et al. Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. J Hum Hypertens 1993; 7: 327-332.
173. Laffel LMB, McGill JB, Gans DJ. The beneficial effect of angiotensin converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria study Group. Am J Med 1995; 99: 497-504.
174. Mathiesen E, Hummel E, Giese J et al. Efficacy of captopril in postponing nephropathy in normotensive insulin-dependent diabetic patients with microalbuminuria. BMJ 1991; 303: 81-87.
175. Rossing P. Promotion, prediction and prevention of progression in diabetic nephropathy. Diabet Med 1998; 15: 900-919.
176. Parving HH, Hommel E, Ruud Jensen B et al. Long-term beneficial effects of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patient. Kidney Int 2001; 60: 228-234.
177. Gasenvoort RT, Sluiter WJ, Hemmelder MU et al. Antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transpl 1995; 10: 1963-1974.
178. The ACE inhibitors in diabetic Nephropathy Trialist Group. Should all type 1 diabetic microalbuminuria patients receive ACE inhibitors? Ann Intern Med 2001; 134: 370-379.
179. Weidmann P, Schneider M, Boehlen LM. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transpl 1995; 10: 39-45.
180. Kasiske BL, Kalil RS, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-138.
181. Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587-593.
182. Mathiesen E, Hommel E, Smith U et al. Efficacy of captopril in normotensive diabetic patients with microalbuminuria: 8 years follow-up. Diabetologia 1995; 38: A46.
183. Hommel E, Jensen B, Parving HH. Long-term effect of captopril on kidney function in normotensive insulin-dependent diabetic patients (IDDM) with diabetic nephropathy [abstract]. J Am Soc Nephrol 1995; 6: 450.
184. Wang PU, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 1993; 341: 1306-1309.
185. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 1995; 47: 1703-1720.
186. Vora JP, Leese GP, Peters JR, Owens DR. Longitudinal evaluation of renal function in non-insulin dependent diabetic patients with early nephropathy: effects of angiotensin-converting enzyme inhibition. J Diabetes Complications 1996; 10: 88-93.
187. Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 2 diabetic patients. Ann Intern Med 1993; 118: 577-581.
188. Sano T, Hotta N, Kawamura T et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study. Diabet Med 1996; 13: 120-124.
189. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997; 20: 1576-1581.
190. Levovitz HE, Weigmann TB, Cnaan A et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 1994; 45: S150-S155.
191. Bakris GL, Copley JB, Vicknair N et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50: 1641-1650.
192. Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. Cochrane Database Syst 2001; 1: CD002183.
193. De Jong PE, Navis GJ, de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999; 354: 352-353.
194. Steffes MW. Affecting the decline of renal function in diabetes mellitus. Kidney Int 2001; 60: 378-379.
195. Ravid M, Lang R, Rachman R et al. Long-term renoprotection effect of angiotensin converting enzyme inhibition in non insulin dependent diabetes mellitus. Arch Intern Med 1996; 156: 286-289.
196. Jerums G. Angiotensin-converting enzyme inhibition and calcium-channel blockade in diabetic patients with microalbuminuria. Nephrology 1997; 3(suppl I): S4.
197. Crepaldi G, Carta Q, Defferari G et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998; 21: 104-110.
198. Velussi M, Brocco E, Frigato F et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216-222.
199. Bakris GL. ACE inhibitors and calcium antagonists alone or combined: is there a difference on progression of diabetic renal disease? J Hypertens 1995; 13(suppl 2): S95-S101.
200. Bakris GL, Weir M, De Quattro V et al. Renal hemodynamic and antiproteinuric response to an ACE inhibitor, trandolapril or calcium antagonist, verapamil, alone or in fixed dose combination in patients with diabetic nephropathy: a randomized multicentre study [abstract]. J Am Soc Nephrol 1996; 7: 1546.
201. Baines LA, White KA, Macleod JM, Bilous RW, on behalf of the ESPRIT Study Group. Angiotensin converting enzyme inhibitors reduce albuminuria but do not affect glomerular structure in type 1 diabetic nephropathy. Diabet Med 1999; 16(suppl 1): A78.
202. Maki DD, Ma JZ, Louis TA, Kasiske BA. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155: 1073-1080.
203. Mogensen CL. Neldam S, Tikkanen I et al. Role of dual blockade of the renin-angiotensin system in hypertensive-, microalbuminuric, noninsulin dependent diabetes: The Calm Study. BMJ 2000; 321: 1440-1444.
204. Ruggenenti P, Perna A, Benini R et al. In chronic nephropathies prolonged ACE inhibition can induce remissions: dynamics of time dependent changes in GFR. J Am Soc Nephrol 1999; 10: 907-1006.
205. Ruggenenti O, Perna P, Benini R et al, for the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Effects of dihydropiridine calcium channel blockers, angiotensin converting enzyme inhibition, and blood pressure control on chronic non diabetic nephropathies. J Am Soc Nephrol 1998; 9: 2096-2101.
206. Peterson JC, Adler S, Burkat JM et al. Blood pressure control, proteinuria, and progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1955; 123: 754-762.
207. Ruggenenti P, Perna A, Remuzzi G. Gruppo Italiano di Studi Epidemiologici in Nephropathy. ACE inhibitors to prevent end-stage renal disease: when to start and why possible never stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 2001; 12: 2832-2837.
208. Herbert LA, Bain RP, Verme D et al. Remission of nephrotic range proteinuria in type 1 diabetes? Collaborative Study Group. Kidney Int 1994; 46: 1688-1693.
209. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of non diabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87.
210. Peters H, Ritz Z. Dosing angiotensin blockers: beyond blood pressure. Nephrol Dial Transpl 1999; 14: 2568-2570.
211. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736.
212. Womer K, Vella J, Sayegh M. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol 2000; 20: 126.
213. Morelli E, Loon N, Meyer TW et al. Effects of converting enzyme inhibition on barrier function in diabetic nephropathy. Diabetes 1990; 39: 79-82.
214. Remuzzi G, Perico N. Protecting single-kidney allografts from long-term functional deterioration. J Am Soc Nephrol 1998; 9: 1321-1332.
215. Luke RG. Pathophysiology and treatment of post-transplant hypertension. J Am Soc Nephrol 1991; 2: S37-S44.
216. First MR, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol 1994; 4: S30-S36.
217. Kasiske BL. Possible causes and consequences of hypertension in stable renal transplant patients. Transplantation 1987; 44: 639-643.
218. Paul LC, Benediktsson H. Post-transplant hypertension and chronic renal allograft failure. Kidney Int 1995; 48: S34-S37.
219. Strandgaard S, Hansen U. Hypertension in renal allograft recipients may be conveyed by cadaveric kidneys from donors with subarachnoid haemorrhage. BMJ 1986; 292: 1041-1044.
220. Frei U, Schindler R, Wieters D et al. Pre-transplant hypertension: a major risk factor for chronic progressive renal allograft dysfunction? Nephrol Dial Transpl 1995; 10: 1206-1211.
221. Bock HA. Chronic rejection and hypertension: a chicken and egg problem. Nephrol Dial Transpl 1995; 10: 1126-1128.
222. Raine AEG. Does antihypertensive therapy modify chronic allograft failure? Kidney Int 1995; 48: S107-S111.
223. Opelz G, Wujciaz T, Ritz E, for the Collaborative Transplant Study. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998; 53: 217-222.
224. Midtvedt K, Neumayer HH. Management strategies for post transplant hypertension. Transplantation 2000; 70: S64-S69.
225. Fricke L, Doehn C, Steinhoff J et al. Treatment of post transplant hypertension by laparoscopic bilateral nephrectomy. Transplantation 1998; 65: 1182-1187.
226. Rao VK. Post transplant medical complications. Surg Clin North Am 1998; 78: 113-132.
227. Curtis JJ. Hypertension following kidney transplantation. Am J Kidney Dis 1994; 23: 471-475.
228. Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 2000; 11: S1-S86.
229. Elliott WJ. Traditional drug therapy of hypertension in transplant recipients. J Hum Hypertens 1998; 12: 845-849.
230. Fassi A, Sangalli F, Colombi F et al. Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. Am J Kidney Dis 1999; 33: 267-275.
231. Ruggenenti P, Perico N, Mosconi L et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43: 706-711.
232. Rahn KH, Barenbrock M, Fritschka E et al. Effect of nitrendipine on renal function in renal transplant patients treated with cyclosporin: a randomised trial. Lancet 1999; 354: 1415-1420.
233. Morales JM, Rodriguez-Paternina E, Araque A et al. Long-term protective effect of a calcium antagonist on renal function in hypertensive renal transplant patients on cyclosporine therapy: a 5 year prospective randomized study. Transpl Proc 1994; 26: 2598-2599.
234. Kloke HJ, Wetzels JFM, Koene RAP, Huysmans FTM. Effects of low-dose nifedipine on urinary protein excretion rate in patients with renal disease. Nephrol Dial Transpl 1998; 13: 646-650.
235. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342: 905-912.
236. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with anti-hypertensive drug therapies. JAMA 1995; 274: 620-625.
237. Olyaei AJ, de Mattos AM, Bennett WM. A practical guide to the managernent of hypertension in renal transplant recipients. Drugs 1999; 58: 1011-1027.
238. Donaho WT, Kosmiski LA, Eckel RH. Drugs causing dyslipoproteinemia. Endocrinol Metab Clin North Am 1998; 27: 667-697.
239. Midtvedt K, Hartmann A, Foss A et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared with lisinopril. Transplantation 2001; 15: 1787-1792.
240. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-1513.
241. Remuzzi G, Perico N. Routine renin-angiotensin system blockade in renal transplantation? Curr Opin Nephrol Hypertens 2002; 11: 1-10.
242. Del Castillo D, Campistol JM, Guirado L et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 1998; 54(suppl 68): S135-S139.
243. Klingbeil AU, Muller HJ, Delles C et al. Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients. Am J Hypertens 2000; 13: 295-300.
244. Hausberg M, Barenbrock M, Hohage H et al. ACE inhibitors versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33: 862-868.
245. Kannel WB, Stampfer MJ, Castelli WP, Vetter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J 1984; 108: 1347-1352.
246. Ojo AO, Hanson JA, Wolfe RA et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307-313.
247. Massy ZA, Guijarro C, Wiederkehr MR et al. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996; 49: 518.
248. Lufft V, Kliem V, Hamkens A et al. Antiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage. Clin Transpl 1998; 12: 409.
249. Barnas U, Schmidt A, Haas M et al. The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure. Nephrol Dial Transpl 1996; 11: 1822-1824.
250. Rell K, Linde J, Morzycka-Michalik M et al. Effect of enalapril on proteinuria after kidney transplantation. Transpl Int 1993; 6: 213-217.
251. Mulhern J, Lipkowitz GS, Braden GL et al. Association of post-renal transplant erythrocytosis and microalbuminuria: response to angiotensin converting enzyme inhibition. Am J Nephrol 1995; 15: 318-322.
252. Oppenheimer F, Flores R, Cofan F et al. Treatment with angiotensin converting enzyme inhibitors in renal transplantation with proteinuria Transpl Proc 1995; 27: 2235-2236.
253. Oka K, Imai E, Moriyama T et al. A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin converting enzyme inhibitor. Nephrol Dial Transpl 2000; 15: 689-695.
254. Grekas D, Dioudis C, Kalevrosoglou I et al. Renal hemodynamics in hypertensive renal allograft recipients: effects of calcium antagonists and ACE inhibitors. Kidney Int 1996; 49(suppl 55): S97-S100.
255. Bochicchio T, Sandoval G, Ron O et al. Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int 1990; 38: 873-879.
256. Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporin-treated renal transplants. Kidney Int 1993; 43: 419-425.
257. Van der Schaaf MR, Hene RJ, Floor M et al. Hypertension after renal transplantation: calcium channel or converting enzyme blockade? Hypertension 1995; 25: 77-81.
258. Wang AY, Yu AW, Lam CW et al. Effect of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without post transplant erythrocytosis. Am J Kidney Dis 2000; 39: 600-608.
259. Azizi M, Rousseau A, Ezan E et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator nacetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996; 97: 839-844.
260. Cole J, Ertoy D, Lin H et al. Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest 2000; 106: 1391-1398.
261. Fried W, Barone-Varelas J, Barone T, Anagnostou A. Effect of angiotensin infusion on extrarenal erythropoietin production. J Lab Clin Med 1982; 99: 520-525.
262. Aeberhard J-M, Schneider P-A, Vallotton MB et al. Multiple site estimates of erythropoietin and renin in polycythemic kidney transplant patients. Transplantation 1990; 50: 613-616.
263. Gossmann J, Thurmann P, Bachmann T et al. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 1996; 50: 973-978.
264. Julian BA, Brantley RR Jr, Barker CV et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998; 9: 1104-1108.
265. Marrero M, Schleffer B, Paxton WG et al. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 1995; 375: 247-250.
266. Glicklich D, Burris L, Urban A et al. Angiotensin-converting enzyme inhibition induces apoptosis in erythtoid precursos and affects insulin-like growt factor 1 in post transplantation erythrocytosis. J Am Soc Nephrol 2001; 12: 1958-1964.
267. Yildiz A, Cine N, Akkaya V et al. Comparison of the effect of enalapril and losartan on post transplantation erythrocytosis in renal transplant patients: prospective randomized study. Transplantation 200 1; 72: 542-544.